The table below shows NovoCure Ltd's income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Revenue
$655.35M
$605.22M
$509.34M
$537.84M
$535.03M
$494.37M
Cost of revenue
$166.88M
$137.18M
$128.28M
$114.87M
$114.88M
$106.50M
Gross profit
$488.47M
$468.04M
$381.06M
$422.97M
$420.15M
$387.87M
R&D
$224.54M
$209.65M
$223.06M
$206.09M
$201.30M
$132.01M
NVCR annual revenue (10-K history)
NovoCure Ltd reported annual revenue of $655.35M for fiscal year 2025. That is up 8.3% from $605.22M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $82.89M (FY 2016) to $655.35M. Figures come from the company's audited annual reports as filed with the SEC.
